GlassScriptPhysician profile
Robert Colella
NPI 1053717744
$2,261.06
in general payments reported to CMS, 2019-2025
12 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.84 · 2022: $340 · 2023: $282 · 2024: $236 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184 · Travel and Lodging: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.95 |
| Travel and Lodging | $651.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $929.05 | 2025 | Watchman |
| E.R. Squibb & Sons, L.L.C. | $295.97 | 2022-2024 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $165.92 | 2024 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $149.65 | 2025 | Attruby |
| Medtronic, INC. | $134.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.65 | 2025 | |
| Merck Sharp & Dohme LLC | $113.18 | 2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $111.07 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $91.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.47 | 2021-2023 | Jardiance |
| Irhythm Technologies, INC. | $41.32 | 2023 | Zio Xt Patch |
| Abbott Laboratories | $21.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Colella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.